BCR and myeloproliferative disorder: In the majority of cases with concurrent BCR::ABL1 translocation and CALR mutation, CML was the first diagnosis, followed by Ph-negative MPN (13/24; 54.16%) (Cabagnols et al., 2015; Loghavi et al., 2015; Diamond et al., 2016; Dogliotti et al., 2017; Gilles et al., 2017; Kandarpa et al., 2017; Blouet et al., 2018; Lewandowski et al., 2018; Balducci et al., 2020; Da Costa et al., 2020; Guidotti et al., 2020; Yoon et al., 2020; Huo et al., 2023), and the Ph-negative MPNs were distributed as follows: four myeloproliferative neoplasm not otherwise specified (MPN, NOS); four PMF; and five ET.